Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

Chemotherapeutic agents are often used to treat cancer. They combat tumor growth, but also have a number of undesirable side ...

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

Bezuclastinib's upcoming data in July 2025 could be a game-changer for COGT, offering a lucrative investment opportunity. See ...

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

Chicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.